ABU DHABI, United Arab Emirates — Whether a newer class of drugs, the sodium glucose cotransporter 2 (SGLT2) inhibitors, should now be considered as first-line therapy in patients with type 2 diabetes ...

Metformin displayed lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had highest risk. (HealthDay News) — Compared with other antidiabetic classes, metformin and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN DIEGO — Sodium-glucose ...

In adults with type 2 diabetes (T2D), the use of SGLT2 inhibitors was associated with lower risks for delirium and all-cause mortality than the use of metformin, with more prominent protective effects ...

A specific type of diabetes medication has been associated with a lower risk of dementia, Alzheimer's and Parkinson's disease in a study published today. The South Korean study followed 358,862 ...

Among patients with type 2 diabetes who have or are at risk for gout, the use of sodium-glucose cotransporter type 2 inhibitors vs sulfonylurea was associated with a lower incidence of gout and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors are the preferred for treating comorbid ...

Analysis of more than 1.5 million records of patients with type 2 diabetes casts light on the risk of dementia and Alzheimer’s disease and potential benefits associated with antidiabetic treatment, ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced the publication of a study titled “Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: a 24-Week, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In patients with ...